Movi Cell Avidity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

LUMICKS Raises $93 Million in Series D Financing
- Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors
AMSTERDAM, April 16, 2021 /PRNewswire/ LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.
The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2 ....

France General , San Francisco , United States , Noord Holland , Kostenloser Wertpapierhandel , Erwin Peterman , Iddo Heller , Olivier Heyning , Kassandra Barbetsea , Gijs Wuite , William Blair , Softbank Vision Fund , Softbank Fund , Softbank Group Corp , T Rowe Price Associates , Farallon Capital Management , Lauxera Capital Partners , Price Associates , Parian Global Management , Gilde Healthcare , Pura Vida Investments , Dynamic Single Molecule , Cell Avidity , Softbank Vision , Movi Cell Avidity , Movi Cell Avidity Analyzer ,